Mayo Clinic researchers have found that first-degree relatives (i.e., parents, siblings, children) of patients with primary biliary cirrhosis (PBC) are more likely to have the biomarker of the disease in their blood.

Injection drug users are still at a very high risk of acquiring hepatitis C (HCV) and hepatitis B (HBV); however, needle-sharing is less common, and users do not become infected as quickly as they did in the past, according to a new study in the September issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD).

The most appropriate system for organ allocation for liver transplants is a subject of continuing debate. In the U.S. the Model for End-Stage Liver Disease (MELD) was introduced in 2002 as a way of prioritizing those with the highest risk of mortality and since that time waiting list mortality and waiting times have decreased with no negative impact on post-transplant survival.

A new study on the outcome of cardiac surgery in patients with liver cirrhosis found that the surgery can safely be performed in patients with milder disease, while those with more severe cirrhosis are less likely to survive.

Two recent Mayo Clinic studies have found that magnetic resonance elastography (MRE), a new imaging technique invented at Mayo Clinic, is an accurate tool for non-invasive diagnosis of liver diseases. The findings will be presented this week at the International Society for Magnetic Resonance in Medicine Annual Meeting in Berlin, Germany, and Digestive Disease Week 2007 in Washington, D.C.

Researchers have yet to report on the concept that hepatitis C virus (HCV) patients who take statins may experience improvements in alanine transaminase (ALT, liver enzymes) levels. Use of statins for hepatitis C has not occurred in the past as the FDA-approved package insert for every statin lists "active liver disease" as a contraindication for use and hepatitis C would certainly qualify as an active liver disease.

For liver transplant recipients without hepatitis C (HCV), survival has improved over time. However, for recipients with HCV, survival has not improved, according to a study in the May issue of Liver Transplantation, the official journal of the American Association for the Study of Liver Diseases (AASLD) and the International Liver Transplantation Society (ILTS).

Measuring liver stiffness using transient elastography can predict severe portal hypertension in patients with hepatitis C-related cirrhosis, according to a new study in the May issue of Hepatology, the official journal of the American Association for the Study of Liver Diseases (AASLD).

The way the liver renews itself may be simpler than what scientists had been assuming. A new study, appearing in the April 13 issue of The Journal of Biological Chemistry, provides new information on the inner workings of cells from regenerating livers that could significantly affect the way physicians make livers regrow in patients with liver diseases such as cirrhosis, hepatitis, or cancer.

Voluntary living liver donors should undergo a careful, but quick, workup and their desire for altruism should not be hampered by negativism from the transplant community, say the authors of a new study in the April issue of Liver Transplantation, the official journal of the American Association for the Study of Liver Diseases (AASLD) and the International Liver Transplantation Society (ILTS).